David Golden
Allergy · Baltimore, MDNPI 1609969708
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by ARS Pharmaceuticals Operations, Inc. at 51.0% of the total. 2025 is the largest year on record at $134,443, 4.0 times the $34,034 reported in 2019. Among allergy clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $976.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ARS Pharmaceuticals Operations, Inc.$101K
- Genentech USA, Inc.$37K
- Aquestive Therapeutics, Inc.$36K
- Kaleo, Inc.$8K
- Phadia US Inc.$7K
- Alk-abello, Inc$4K
- plus $5K from 18 others
Across 93 payments — averaging $2140.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$139K
- Regeneron$33K
- Novartis$17K
- Aquestive Therapeutics, Inc.$11K
What the payments were for
- Consulting fees$79,25640%
- Speaking & faculty fees$95,21548%
- Travel & lodging$18,6159%
- Food & beverage$4,1982%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. | 67 | $100,713 |
| Genentech USA, Inc. | 43 | $36,901 |
| Aquestive Therapeutics, Inc. | 11 | $35,544 |
| Kaleo, Inc. | 4 | $7,672 |
| Phadia US Inc. | 7 | $7,181 |
| Alk-abello, Inc | 5 | $4,355 |
| Seqirus USA Inc | 1 | $1,500 |
| Sandoz | 1 | $1,134 |
| Blueprint Medicines Corporation | 1 | $600 |
| Sanofi | 2 | $472 |
| GSK | 16 | $262 |
| Pharming Healthcare, Inc. | 2 | $188 |
| AstraZeneca | 8 | $185 |
| Novartis | 9 | $169 |
| CSL Behring | 7 | $137 |
| Optinose US, Inc. | 4 | $74 |
| Pfizer | 4 | $68 |
| Shire North American Group Inc | 2 | $38 |
| Circassia Inc. | 2 | $29 |
| Boehringer Ingelheim | 2 | $26 |
| Grifols USA, LLC | 1 | $18 |
| Covis Pharma GmbH | 1 | $17 |
| Bio Products Laboratory USA, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$197,308 in reported general payments places this provider in the 95th percentile of 29 allergy providers in Maryland.
Other allergy in Baltimore
- Jody TverskyBaltimore$175K
- Sarbjit SainiBaltimore$174K
- Newton AdkinsonBaltimore$61K
- Peter CreticosBaltimore$22K
- Gitika DhillonBaltimore$8K
- Alkis TogiasBaltimore$67
- Huamin LiWheaton$576K
- Jonathan MatzWhite Marsh$147K
- Brett CoonsJb Andrews$49K
- David SchwartzBethesda$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.